3 Quality Stocks Built For A Pricey Market
This article identifies three quality stocks—TransMedics Group (TMDX), Privia Health Group (PRVA), and Savaria (SIS)—that are well-suited for a market with stretched valuations. These companies are highlighted for their strong fundamentals, consistent earnings, and effective risk controls. The analysis emphasizes their resilience and potential for growth in a volatile economic environment.
Form 144 Privia Health Group For: 2 July By Investing.com
This article reports on a Form 144 filing for Privia Health Group on July 2nd. It provides key financial metrics for various indices and commodities, including market performance and trading volumes. The piece also lists several trending and most actively traded stocks, alongside other financial news and market analysis from Investing.com.
Form 144 Privia Health Group For: 2 July By Investing.com
This article from Investing.com is a brief notice about a Form 144 filing for Privia Health Group on July 2nd. It indicates that such a form has been released, likely pertaining to the sale of restricted securities by company insiders. The article includes a variety of market data and news headlines as surrounding content.
PRVA (NASDAQ: PRVA) insider sales reported, with restricted stock vesting noted
A recently filed Form 144 for Privia Health Group, Inc. (NASDAQ: PRVA) indicates sales by an affiliated holder and outlines several restricted stock vesting events across March, April, and May 2026. The filing also details multiple brokered sales by David Mountcastle from April to June 2026, totaling various share counts and impressive proceeds. The document highlights routine dispositions connected to vested restricted stock and specific brokered transactions.
Director at Privia Health (PRVA) sells 135,498 shares after option exercise
Privia Health Group, Inc. director Matthew Shawn Morris reported exercising 135,498 stock options at $2.00 per share and subsequently selling 135,498 common shares in open-market transactions. These sales, totaling approximately $3.57 million, were conducted under a pre-arranged Rule 10b5-1 trading plan. Morris retains significant direct and indirect equity interests in the company despite these transactions.
Privia Health(PRVA.US) Director Sells US$3.83 Million in Common Stock
NULL
Privia Health (PRVA) director sells 151,322 shares after exercising options
Privia Health Group, Inc. (PRVA) director Matthew Shawn Morris sold 151,322 shares after exercising stock options on June 26 and June 29, 2026. The shares were acquired at $2.00 each and sold in open-market transactions at a weighted average price of approximately $25.33 per share, under a Rule 10b5-1 trading plan. Following these transactions, Morris directly holds 76,651 shares, with additional shares held indirectly through a trust and an LLC.
Privia Health (NASDAQ: PRVA) CFO sells 17,196 exercised shares
Privia Health's EVP & CFO, David Mountcastle, exercised options to acquire 17,196 shares of common stock at $2.00 per share and subsequently sold the same number of shares at a weighted average price of $25.18 per share. This transaction, executed on June 26, 2026, was conducted under a pre-arranged Rule 10b5-1 trading plan. After the sale, Mountcastle directly holds 211,462 shares, with an additional 8,695 shares held indirectly through his spouse.
PRVA (NASDAQ) Form 144: 17,196 shares linked to option exercise filed 06/26/2026
A Form 144 filing by Privia Health Group, Inc. (PRVA) indicates a proposed sale of 17,196 shares on June 26, 2026, linked to a stock option exercise and facilitated by Fidelity Brokerage Services. The filing also details prior dispositions by David Mountcastle in April and May 2026, totaling 17,336 shares with associated cash proceeds. This regulatory notice helps ensure transparency regarding sales of restricted or control securities by affiliates.
Privia Health Group, Inc. Actuals & Estimates (NASDAQ:PRVA)
This article provides an overview of Privia Health Group, Inc. (NASDAQ: PRVA) stock, including its current price, performance, and analyst forecasts. It details financial actuals and estimates, frequently asked questions about the company's financials, and advice on how to invest.
Privia Health Group Inc (PRVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Privia Health Group Inc (PRVA), detailing its current price momentum score as 9.47 and ranking it 31 out of 76 in its industry. It identifies a trading range between $22.13 (support) and $27.36 (resistance), suggesting suitability for range-bound swing trading. The analysis includes various technical indicators and moving averages, largely pointing to a "Buy" signal for the stock.
Privia Health Group (PRVA) Stock Could Be 24.7% Undervalued After Strong Growth
Privia Health Group (PRVA) has reported significant revenue and net profit growth, leading to increased investor attention. While some valuation models suggest the stock is undervalued by up to 24.7%, its high P/E ratio compared to the industry and peers indicates potential valuation risk. Investors are encouraged to assess the details further to balance the potential rewards against the inherent risks.
Privia Health Group Stock - Long-term model and volatility under review
This article examines Privia Health Group (PRVA) stock, focusing on its long-term business model and risk profile, given elevated valuation metrics and recent share price volatility. Despite no fresh corporate news, the company's physician enablement model, which aggregates independent physician groups onto a technology-enabled platform, is analyzed for its durability, revenue drivers, competitive landscape, and regulatory risks. The stock, trading in the mid-$20s with a market cap of approximately $2.9 billion, is still considered a growth story.
Privia Health Group Inc (PRVA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Privia Health Group Inc (PRVA), detailing its current earnings forecast score, average price target from analysts, and analyst ratings, which largely suggest a "Buy" trend. It also includes expected revenue for the next quarter, historical EPS performance, and a peer comparison within the Healthcare Providers & Services industry.
Privia Health Group Inc (PRVA) Financial Health: Profitability & Balance Sheet Analysis
Privia Health Group Inc (PRVA) has a robust financial status with a current financial score of 7.32, ranking 48 out of 76 in its industry. The company reported a 25.78% year-over-year increase in quarterly revenue, reaching $603.85 million, and a 27.39% increase in net profit. Its operating efficiency is noted as high.
Privia Health Group Inc (PRVA) Valuation: PE, PB & Fair Value Analysis
Privia Health Group Inc (PRVA) has a current valuation score of 6.38, ranking 66 out of 76 in the Healthcare Providers & Services industry. Its P/E ratio is 132.04, which is significantly below its recent high and above its recent low. However, relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Why (PRVA) Price Action Is Critical for Tactical Trading
This article analyzes Privia Health Group Inc. (NASDAQ: PRVA) stock, highlighting critical price action for tactical trading. It identifies strong near- and mid-term sentiment, tests support levels, and provides exceptional risk-reward setups with specific targets and stop losses. The analysis includes AI-generated signals and multi-timeframe insights for various trading strategies.
Renaissance Group LLC Invests $7.78 Million in Privia Health Group, Inc. $PRVA
Renaissance Group LLC has made a significant investment in Privia Health Group, acquiring 327,970 shares valued at approximately $7.78 million in the fourth quarter. This move contributed to the substantial institutional ownership of Privia Health, which stands at 94.48%. The company reported strong financial results, surpassing both earnings and revenue expectations, and holds an average analyst rating of "Moderate Buy" with a target price of $31.15.
Privia Health Group, Inc.
This page provides an analyst forecast for Privia Health Group, Inc. (PRVA), featuring market data, financial metrics, and analyst consensus. It includes sections for current and forward analyst estimates on revenue, EBITDA, EPS, and net income, along with historical price targets and recommendation trends.
What Privia Health Group (PRVA)'s New Jersey Neurology Anchor Deal Means For Shareholders
Privia Health Group (PRVA) recently partnered with Neurology Group of Bergen County to enter the New Jersey market, integrating a 25-clinician practice onto its platform by year-end 2026. This move aligns with Privia's strategy to scale its physician enablement model across new states, aiming to boost revenue and earnings. While the partnership expands Privia's reach, investors are advised to consider its impact on profitability, especially given the company's thin margins and increasing operational costs, which are critical for supporting its current valuation.
Understanding Momentum Shifts in (PRVA)
The article identifies a mid-channel oscillation pattern for Privia Health Group Inc. (PRVA) with a neutral near-term sentiment that could moderate mid-term weakness. It highlights an exceptional 40.0:1 risk-reward setup targeting an 11.5% gain versus 0.3% risk. Three distinct AI-generated trading strategies are provided: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, each with specific entry, target, and stop-loss levels.
Q1 Rundown: Privia Health (NASDAQ:PRVA) Vs Other Healthcare Technology for Providers Stocks
This article provides a Q1 rundown of several healthcare technology for providers stocks, including Privia Health (NASDAQ:PRVA), Omnicell (NASDAQ:OMCL), Evolent Health (NYSE:EVH), and Astrana Health (NASDAQ:ASTH). It details their Q1 financial performance, highlighting revenue beats and misses, EPS results, and market reactions. The article also touches on broader market updates, discussing shifts from AI concerns to geopolitical risks in late 2025 and early 2026.
PRVA News | PRIVIA HEALTH GROUP INC (NASDAQ:PRVA)
This page provides news and analysis for Privia Health Group Inc (NASDAQ:PRVA), compiling recent headlines from ChartMill and Zacks. The articles cover quarterly earnings reports, revenue and EPS performance, and strategic developments such as market expansion into New Jersey. It also features comparative analyses against other stocks, like TBRG.
Q1 Rundown: Privia Health (NASDAQ:PRVA) Vs Other Healthcare Technology for Providers Stocks
This article analyzes the Q1 performance of Privia Health (NASDAQ:PRVA) and other healthcare technology for providers stocks, including Omnicell (NASDAQ:OMCL), Evolent Health (NYSE:EVH), and Astrana Health (NASDAQ:ASTH). It highlights key revenue and EPS figures, analyst expectations, and market reactions, noting Privia Health's revenue beat but EPS miss, Omnicell's exceptional quarter, Evolent Health's mixed results, and Astrana Health's strong revenue growth. The sector generally showed strong Q1 results with revenues beating estimates and share prices rising.
A Look at Privia Health Group Inc (PRVA) After 3.4% Gain -- GF V
Privia Health Group Inc (PRVA) saw a 3.4% stock gain, despite a year-to-date decline. The company is considered "Modestly Undervalued" by GuruFocus, with a GF Value estimate of $27.19 against its current price of $21.37. However, insider selling worth $8.2 million over the last three months signals caution for potential investors.
PRVA - Privia Health Group Inc Stock Price and Quote
This page provides a comprehensive overview of Privia Health Group Inc (PRVA) stock, including its latest trading data, key financial metrics, performance indicators, and recent news and analyst ratings spanning several years. It also details recent insider transactions by company executives and directors.
Is Privia Health Stock a Buy After Hedge Fund Rubicon Founders Added Over 175,000 Shares to Its Position?
Hedge fund Rubicon Founders significantly increased its stake in Privia Health Group (NASDAQ:PRVA) by 175,142 shares during the first quarter, representing an estimated transaction value of $3.95 million. This move makes Privia Health account for 88.92% of the fund's reportable AUM, signaling strong bullish sentiment. The article highlights Privia Health's solid financials, including $2.25 billion in TTM revenue and a scalable business model, suggesting it could be a worthwhile long-term investment.
Is Privia Health Stock a Buy After Hedge Fund Rubicon Founders Added Over 175,000 Shares to Its Position?
Rubicon Founders, a hedge fund, significantly increased its stake in Privia Health Group (NASDAQ:PRVA) by 175,142 shares during Q1 2026, bringing its total holding to 5,948,664 shares valued at $122.36 million. This substantial investment means Privia Health now constitutes 88.92% of the fund's reportable AUM, indicating a strong bullish outlook. Despite a recent stock price decline, Privia Health demonstrates robust financials with increasing revenue and net income, positioning it as a potential long-term investment.
Free cash flow per share of Privia Health Group, Inc. – NASDAQ:PRVA
The article provides financial data on the free cash flow per share for Privia Health Group, Inc. (NASDAQ: PRVA) via TradingView. It highlights that the market was closed at the time of publication and offers various financial and technical analysis tools for the stock.
Privia Health Group Enters New Jersey
Privia Health Group has announced its expansion into New Jersey through a partnership with three established physician practices: Mercer Medical Group, Ewing Medical Group, and Hamilton Medical Group. This collaboration marks Privia Health's 14th state and aims to empower physicians with advanced technology, administrative support, and an elevated care model to improve patient outcomes and practice efficiency. The initiative underscores Privia Health's commitment to transforming healthcare delivery by strengthening independent practices.
PRVA Maintained by Barclays -- Price Target Lowered to $24.00
Barclays analyst Andrew Mok has maintained an Equal-Weight rating for Privia Health Group Inc (PRVA) but lowered the price target to $24.00 from $25.00, reflecting a cautious outlook amid reassessed growth prospects. Despite this, GuruFocus indicates PRVA is undervalued by 18.0% with a GF Value™ of $27.14 and boasts a strong GF Score™ of 88, though significant insider selling of $9.1 million in the last three months raises some investor concerns.
New Jersey neurology care to expand as Privia joins 25-clinician group
Privia Health (Nasdaq: PRVA) is expanding its national network by entering New Jersey, its 25th state, through a partnership with the Neurology Group of Bergen County (NGBC). NGBC, a practice with 25 adult and pediatric clinicians, will serve as the anchor for Privia Medical Group—New Jersey and is expected to be integrated into the Privia Platform by year-end 2026. This collaboration aims to provide enhanced support and resources to community clinicians, allowing them to care for patients across various reimbursement models and leverage interoperable solutions for better care insights.
Avoiding Lag: Real-Time Signals in (PRVA) Movement
The article analyzes Privia Health Group Inc. (NASDAQ: PRVA), indicating weak near and mid-term sentiment but a neutral long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional short setup targeting 10.5% downside. The analysis also provides institutional trading strategies for various risk profiles, including position, momentum breakout, and risk hedging strategies.
Privia Health (PRVA) director awarded 8,463 RSUs in equity grant
Privia Health Group director Pamela O. Kimmet was granted 8,463 restricted stock units (RSUs) on May 20, 2026, under the company’s 2021 Omnibus Incentive Plan. These RSUs will vest on the earlier of the day before the 2027 annual shareholder meeting or one year after the grant date. Following this transaction, Kimmet directly holds 34,172 common shares of Privia Health.
PRVA Technical Analysis | Trend, Signals & Chart Patterns | PRIVIA HEALTH GROUP INC (NASDAQ:PRVA)
This article provides a technical analysis of PRIVIA HEALTH GROUP INC (NASDAQ:PRVA), assigning it a low technical rating of 2 out of 10 due to negative short and medium-term trends, with a neutral long-term outlook. Despite the poor overall rating, the stock shows potential as a setup opportunity due to consolidating prices and reduced volatility. The analysis also details support and resistance levels, individual indicator signals like RSI and MACD, and identified candlestick and chart patterns.
Privia Health Group shareholders approve all proposals at annual meeting
Privia Health Group shareholders approved all three proposals at their 2026 Annual Meeting, including the election of three Class I directors, an advisory vote on executive compensation, and the ratification of PricewaterhouseCoopers LLP as their independent auditor. The healthcare technology company, with a market cap of $2.85 billion and nearly 25% revenue growth, also recently reported mixed Q1 2026 earnings, exceeding revenue projections but falling short on EPS.
Privia Health Group (PRVA) director awarded 8,463 restricted stock units
Privia Health Group director Matthew Shawn Morris was granted 8,463 restricted stock units (RSUs) on May 20, 2026, under the company's 2021 Omnibus Incentive Plan. These RSUs were awarded at a grant price of $0.00 per share and will vest by the earlier of the day preceding the 2027 annual meeting of stockholders or the first anniversary of the grant date. Following this award, Morris directly holds 76,651 common shares, with additional indirect holdings through a trust and Emerald Family, LLC.
Privia Health Group shareholders approve all proposals at annual meeting
Privia Health Group Inc. (NASDAQ:PRVA) shareholders approved all three proposals at its 2026 Annual Meeting of Stockholders. These approvals included the election of three Class I directors, an advisory vote on executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm. The company also recently reported mixed first-quarter 2026 earnings, exceeding revenue projections but falling short on EPS.
Privia Health (PRVA) director awarded 8,463 restricted stock units in equity grant
Privia Health Group, Inc. director Nancy G. Cocozza was granted 8,463 restricted stock units (RSUs) on May 20, 2026, as per a Form 4 filing. This equity award, granted at no cash cost, will vest on the earlier of the day before Privia's 2027 annual meeting or the first anniversary of the grant date. Following this transaction, Cocozza's direct holdings in the company total 42,814 shares.
Privia Health (PRVA) director receives 8,463 restricted stock units in equity grant
Privia Health director Lance Berberian was granted 8,463 restricted stock units (RSUs) under the company’s 2021 Omnibus Incentive Plan on May 20, 2026. These RSUs will vest on the earlier of the day before the 2027 annual stockholders’ meeting or the first anniversary of the grant date and represent routine director compensation. Following this grant, Berberian directly holds 16,131 shares of Privia Health common stock.
Director at Privia Health (PRVA) receives 8,463 RSU grant as board compensation
Privia Health director David P. King was granted 8,463 Restricted Stock Units (RSUs) on May 20, 2026, as part of his board compensation under the company's 2021 Omnibus Incentive Plan. These RSUs, which have an effective grant price of $0.00, will vest on the earlier of the day before the company's 2027 annual meeting or the first anniversary of the grant date. Following this award, King directly holds 50,775 common shares, indicating a routine compensation event rather than an open-market transaction.
Privia Health (NASDAQ: PRVA) holders approve directors, pay and auditor
Privia Health Group, Inc. (NASDAQ: PRVA) announced that its stockholders approved all proposals at the 2026 Annual Meeting. Key approvals included the election of three Class I directors (Nancy Cocozza, David King, and Francis Soistman), the advisory approval of named executive officer compensation, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The decisions reflect strong shareholder support for the company's governance and compensation practices.
Privia Health (PRVA) director receives 8,463 restricted stock units as equity award
Privia Health Group director Francis S. Soistman Jr. was granted 8,463 restricted stock units as an equity award on May 20, 2026, under the company's 2021 Omnibus Incentive Plan. These units, valued at $0.00 per unit, will vest on the earlier of the day before Privia's 2027 annual stockholders’ meeting or the first anniversary of the grant date. This transaction is categorized as a compensation-based equity grant and not an open-market purchase.
BMO Capital Initiates Coverage of Privia Health Group (PRVA) with Outperform Recommendation
BMO Capital Markets has initiated coverage on Privia Health Group (PRVA) with an "Outperform" rating. This new coverage suggests a positive outlook from the firm regarding Privia Health's stock performance. Investors and market watchers will likely monitor PRVA's performance following this recommendation.
Privia Health Group CEO & Director Parth Mehrotra Sells 47% Of Holding
Parth Mehrotra, CEO & Director of Privia Health Group, recently sold shares worth US$2.7 million, reducing his holding by 47%. This was the largest insider sale within the last year, suggesting insiders might view lower prices as reasonable, although the company is profitable and growing. While insider selling can be a weak negative signal, Mehrotra still retains a significant stake, and insiders collectively own about 0.6% of the company.
Insider Selling: Privia Health Group (NASDAQ:PRVA) CEO Sells 105,439 Shares of Stock
Privia Health Group CEO Parth Mehrotra sold 105,439 shares of company stock for approximately $2.38 million on May 11th, reducing his direct ownership by 18.98%. This transaction, conducted under a pre-arranged Rule 10b5-1 plan, was primarily to cover tax withholding obligations from vesting equity awards. Despite other recent insider sales by Mehrotra, analysts maintain a "Moderate Buy" rating for PRVA, with a consensus target price of $31.23, following strong Q1 earnings that surpassed expectations.
Privia Health Group (NASDAQ:PRVA) CFO Sells $76,501.00 in Stock
Privia Health Group CFO David Mountcastle sold 3,385 shares of PRVA stock for approximately $76,501 on May 11th, primarily to cover tax withholding obligations from vested equity awards. This sale reduced his stake by 1.58%, although he still holds 211,462 shares valued at over $4.7 million. The company recently exceeded quarterly earnings and revenue expectations, and analysts maintain a "Moderate Buy" consensus rating with a target price above current trading levels.
Privia Health Group (Nasdaq:PRVA) - Stock Analysis
Privia Health Group (NASDAQ:PRVA) is a national physician-enablement company with a market cap of US$2.9 billion, currently trading 42% below its estimated fair value. Analysts forecast a 32.52% annual earnings growth, supported by expansion into new markets and growing value-based care. Recent insider selling and a Q1 2026 EPS miss, despite revenue growth, present some headwinds for the company.
Privia Health Group's (NASDAQ:PRVA) Earnings May Just Be The Starting Point
Privia Health Group (NASDAQ:PRVA) reported strong earnings, yet investors seemed underwhelmed. Analysis of the accrual ratio, which measures how well profit is backed by free cash flow, revealed a negative ratio of -0.37, indicating that statutory earnings were significantly less than free cash flow. This suggests the company's underlying earnings potential might be better than reported profits suggest, with EPS also up 22% annually over the last three years.
Privia Health Group's (NASDAQ:PRVA) Earnings May Just Be The Starting Point
Privia Health Group (NASDAQ:PRVA) posted strong earnings, but investors seemed underwhelmed. Analysis of the accrual ratio from cash flow, which indicates how well profit is backed by free cash flow, suggests the company's underlying earnings potential is better than its statutory profit. The negative accrual ratio of -0.37 and significant free cash flow of US$138m compared to US$21.8m in profit indicate strong conversion, alongside a 22% annual EPS growth over three years.
